Publications

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-Naive Metastatic Clear-Cell Renal Cell Carcinoma

AuthID
P-00T-BPV

Author(s)

Bedke, J

Albiges, L

Capitanio, U

Giles, RH

Hora, M

Lam, TB

Ljungberg, B

Marconi, L

Klatte, T

Volpe, A

Abu Ghanem, Y

Dabestani, S

Fernandez Pello, S

Hofmann, F

Kuusk, T

Tahbaz, R

Powles, T

Bex, A

Document Type

Article

Year published

2021

Published

in EUROPEAN UROLOGY, ISSN: 0302-2838

Volume: 79, Issue: 3, Pages: 339-342 (4)

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.eururo.2020.12.005

Pubmed: 33357997

Scopus: 2-s2.0-85099364654

Wos: WOS:000694859600018

Source Identifiers

ISSN: 0302-2838

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-Naive Metastatic Clear-Cell Renal Cell Carcinoma

Useful Links

Get Help

Federated Authentication (Click on the image)

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-Naive Metastatic Clear-Cell Renal Cell Carcinoma

Useful Links

Get Help